![]() Our company provides many development opportunities such as workshops, specific trainings and ability to participate in international conferences. For sport enthusiast we offer co-funding of the Multisport card. We offer fresh fruits in break room for our workers to enjoy throughhout the day. Team outings and fun events are being frequently organised. We make sure that our staff feel welcome, respected and appreciated. We encourage our employees to work, brainstorm and problem solve together. Our employees can choose their working hours, starting anytime from 7 AM to 10 AM. Every employee is firstly offered a three-month trial period, followed by an employment contract for an indefinite duration with a competitive salary.Ĭaptor Therapeutics currently consists of more than 35 employees, creating young and enthusiastic team of scientist both at PhD and Masters level with experties in molecular biology and early stages of drug development, supported by experienced professionals. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.Flexible work schedules and employment conditions TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide an optimal medical benefit. In unresectable HCC, the best reported outcome is the combination of Atezolizumab (Tecentriq®) plus Bevacizumab (Avastin®), where 19.2 months median Overall Survival (OS) and 29.8% Overall Response Rate (ORR) were reported in the IMbrave150 study, indicating that there remains a dramatic need for new treatments.Ĭaptor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. In patients diagnosed early, surgical removal of the tumor remains the only effective therapy. With ~700,000 new cases each year, HCC constitutes the second most common cause of cancer mortality. HCC, a form of liver cancer, constitutes a significant unmet medical need since most patients are diagnosed at a late stage of the disease, and present treatments bring limited benefits in terms of overall survival rate. The purpose of Project CT-01 is to develop, based on targeted protein degradation technology, a drug candidate which will stop the progress of hepatocellular carcinoma (HCC) and potentially offer significant benefits for patients. The company will provide more detailed information during an online investor call next week. Both sets of in vivo data provide further evidence of the potential of the Company's Optigrade™ targeted protein degradation platform to discover and develop molecular glue- and bifunctional-type degraders with good druggable properties against high-value targets. We will now look to progress one of these compounds towards Investigational New Drug Application (IND)-enabling studies."ĬT-01 is Captor Therapeutics' second pipeline project to produce in vivo data recently, following positive pharmacological results from the CT-03 project. 25, 2022 (GLOBE NEWSWIRE) - Captor Therapeutics S.A. The strong regression of tumors in a liver cancer model shown in our proof-of-concept study is extremely encouraging and supports further work on the CT-01 project. "Hepatocellular carcinoma is a very common cancer, but remains difficult to treat with few effective therapies and poor prognosis for most patients. "These preclinical data represent a significant milestone in the development of one of our core pipeline projects," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics. Simultaneously, the data demonstrate the tolerability of both CT-01 candidates, as no treatment-related toxicity was observed. Strong and comparable efficacy was demonstrated in both therapeutic groups (100mg/kg bid and 300mg/kg bid). The in vivo proof-of-concept data confirm the potent antitumor activity of two CT-01 lead compounds in a liver cancer mouse xenograft model and demonstrate that oral administration of these two CT-01 candidates results in complete tumor regression in a Hep 3B2.1-7 mouse model of HCC. ![]() (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, announces preclinical proof-of-concept data from one of its core pipeline projects designated CT-01, which is focused on the development of TPD therapy for hepatocellular carcinoma (HCC). 13, 2022 (GLOBE NEWSWIRE) - Captor Therapeutics S.A. Results support advancement of CT-01 compounds towards IND expected in late 2022.Data confirm strong anticancer activity of two lead compounds in CT-01 program. ![]()
0 Comments
Leave a Reply. |